Prognostic and Predictive Biomarkers in Ovarian Cancer

Dear Colleagues,

In 2023, nearly 20,000 women in the USA would have received a diagnosis of ovarian cancer (OC), and the number of those that succumb to it will surpass that of any other gynecological cancer. According to the American Cancer Society (ACS), if diagnosed early, about 94% of women with OC will live longer than 5 years after diagnosis. This highlights a critical unmet medical need for effective prognostic or predictive biomarkers that can help diagnose disease likelihood or predict favorable response to a specific medical intervention, respectively. Currently, doctors depend on a variety of tests that may or may not include transvaginal ultrasound, imaging data and blood tests for elevated CA-125, among others, to diagnose OC. Biopsies and mutational analysis are usually necessary for further staging for personalized treatment. Over the last few decades, there has been an overwhelming surge in research that has identified novel clinical, genetic, immune and molecular biomarkers that increase hope for a better future for women with ovarian cancer. We aim to collate relevant research data to better identify relevant biomarkers that will facilitate timely diagnosis and targeted treatment to ensure prolonged survival in women with OC. 

Dr. Jayakumar Nair
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.